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Abstract Noninvasive measurement of tissue iron levels can
be assessed using T2* magnetic resonance imaging (MRI) to
identify and monitor patients with iron overload. This study
monitored cardiac siderosis using T2* MRI in a cohort of 19
heavily iron-overloaded patients with β-thalassemia major
receiving iron chelation therapy with deferasirox over an
18-month period. Overall, deferasirox therapy significantly
improved mean ± standard deviation cardiac T2* from a
baseline of 17.2±10.8 to 21.5±12.8 ms (+25.0%; P=0.02). A
concomitant reduction in median serum ferritin from a
baseline of 5,497 to 4,235 ng/mL (−23.0%; P=0.001), and
mean liver iron concentration from 24.2±9.0 to 17.6±
12.9 mg Fe/g dry weight (−27.1%; P=0.01) was also seen.
Improvements were seen in patients with various degrees of
cardiac siderosis, including those patients with a baseline
cardiac T2* of <10 ms, indicative of high cardiac iron
burden. These findings therefore support previous observa-
tions that deferasirox is effective in the removal of myocardial
iron with concomitant reduction in total body iron.
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Introduction
Myocardial siderosis is a leading cause of cardiac morbidity
and mortality in regularly transfused patients with β-
thalassemia [1, 2]. Adequate chelation therapy can reverse
the deleterious effects of cardiac iron overload [3]; however,
it is also important for an iron chelator to prevent myocardial
iron accumulation while reducing total body iron burden.
Measurement of cardiac T2* by magnetic resonance imaging
(MRI) is a noninvasive direct method that has been
developed for detecting and quantifying tissue iron levels
and identifying patients with iron overload [4, 5].
Deferasirox (Exjade®; Novartis Pharma AG, Basel,
Switzerland),aonce-daily,oralironchelatorhasdemonstrated
efficacy in reducing hepatic and body iron burden as assessed
by liver iron concentration (LIC) and serum ferritin measure-
ments in chronically transfused patients with a range of
anemias [6–8]. Preclinical evaluation and initial clinical
studies have demonstrated the efficacy of deferasirox in the
removal of cardiac iron [9–11]. More recently, a prospective
study of deferasirox in a large group of patients with β-
thalassemia and a longitudinal analysis of myocardial T2* in
iron-chelated patients have provided further evidence sup-
porting the use of deferasirox in removing and preventing
myocardial iron accumulation [12–14].
Theefficacyandsafetyoflong-termtreatmentwithICL670
in β-thalassemia patients with transfusional hemosiderosis
(ESCALATOR) trial was conducted to evaluate the efficacy
and safety of deferasirox specifically in regularly transfused
patients with β-thalassemia who had previously received
deferoxamine (DFO; Desferal®; Novartis Pharma AG, Basel,
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DOI 10.1007/s00277-009-0838-zSwitzerland) and/or deferiprone (Ferriprox®; Apotex Inc.,
Toronto, ON, Canada) [15]. Sultan Qaboos University
Hospital, Muscat Oman, was one of the participating sites,
and cardiac T2* MRI was introduced at the center in 2006.
Therefore, after completing the 1-year core phase of the
ESCALATOR trial, cardiac iron was evaluated in Omani trial
patients as part of standard-of-care practice. The aim of this
study was to monitor the effects of deferasirox on myocardial
siderosis in these patients enrolled at a single center in Oman
using T2* MRI for a further 18-month period.
Patients and methods
This study was conducted on a subgroup of 19 patients,
from the ESCALATOR trial to monitor the effects of
deferasirox on myocardial siderosis in patients enrolled at
the Sultan Qaboos University Hospital in Oman using T2*
MRI over an 18-month period.
The ESCALATOR trial was a prospective, open-label,
1-year, multicenter, Phase IV study conducted in the Middle
East. Details of the design and inclusion criteria for the
ESCALATOR trial have been described in detail previously
[15]. The ESCALATOR trial enrolled male or female
patients (≥2 years old) with β-thalassemia and transfusional
ironoverloadwhohadbeenunsuccessfullychelatedwithprior
mono- or combination therapy with DFO and/or deferiprone
(due to unacceptable toxicity, poor response to previous
chelator, or documented noncompliance of taking <50% of
prescribed doses in previous year). Patients were required
to have a LIC of ≥2m gF e / gd r yw e i g h t( d w ) ,s e r u m
ferritin levels of ≥500 ng/mL, alanine aminotransferase
levels of <300 U/L, and normal renal function.
Measurement of cardiac T2* by MRI was performed using
the single breath-hold, multi-echo T2* protocol described by
Westwood et al. [16]. A 10-mm thick single slice was
obtained in the short axis through the midventricle during a
single breath-hold. The T2* sequence was acquired at eight
echo times from 2.5 to 18.0 ms in 2.18 ms increments. For
analysis, a full-thickness region was chosen through the
interventricularseptum.TheT2*valueswerecalculatedusing
CMRtools (Cardiovascular Imaging Solutions, London, UK).
LIC was measured bya R2MRI technique as described by St.
Pierre et al. [17]. Echo times of 6, 9, 12, 15, and 18 ms were
collected with a slide thickness of 5 mm.
Allpatientsreceiveddeferasirox20mg/kg/dayasastarting
dose with routine dose adjustments performed in response to
changes in serum ferritin levels and safety markers. Patients
had therefore been receiving once-daily deferasirox for
12 months prior to the first cardiac T2* assessment (baseline).
Patients continued on deferasirox throughout the 18-month
period of this present evaluation with dose adjustments
conducted as per the ESCALATOR trial protocol [15]. Dose
adjustments in increments of 5 or 10 mg/kg/day were
performed based on efficacy (serum ferritin levels) and
safety markers (dose range 0–40 mg/kg/day). Doses were
increased if serum ferritin rose to ≥1,000 ng/mL above
baseline on two consecutive visits or to >2,500 ng/mL
without a decreasing trend. Deferasirox was interrupted if
serum ferritin fell to ≤500 ng/mL on two consecutive visits
and resumed if serum ferritin rose to ≥1,000 ng/mL. Doses
were reduced for elevated serum creatinine, urinary protein/
creatinine ratio, and transaminases and in response to
adverse events.
Statistical analysis Markers of deferasirox efficacy, cardiac
T2*, LIC, and serum ferritin were measured at 6 and
18 months. Baseline characteristics of patients were
compared at 6 months and at 18 months using one-way
analysis of variance for continuous variables and Student’s
t test for paired variables. All P values are two-sided and
considered significant with P≤0.05. Statistical analysis was
performed using SPSS statistical software v14 (SPSS, Inc.,
Chicago, IL).
Results
All 19 patients who participated in this study were assessed
for myocardial iron loading by T2* MRI and total body
iron load using serum ferritin measurements and LIC by
biopsy (Table 1). All patients completed 18 months of
extended evaluation.
Baseline cardiac T2* (mean ± standard deviation, 17.2±
10.8 ms) was indicative of myocardial iron accumulation
(normal T2* is considered to be >20 ms), and baseline
serum ferritin (median 5,497 ng/mL) signified a high total
Table 1 Baseline patient characteristics
All patients (n=19)
Mean age (range; years) 18 (10–29)
Female:male (n) 11:8
Race (caucasian
a:oriental:other; n) 19:0:0
History of hepatitis C
b, n (%) 5 (26.3)
Splenectomy, n (%) 7 (36.8)
Mean ± SD baseline cardiac T2*, ms 17.2±10.8
Median baseline serum ferritin (range; ng/mL) 5,497 (2,560–16,378)
Mean ± SD prebaseline LIC
c (mg Fe/g dw) 24.2±9.0
SD standard deviation, LIC liver iron concentration, dw dry weight
aArab including some of Indian genetic background
bInvestigator-reported patient history
cThese values were measured 3–6 months prior to baseline T2* MRI
406 Ann Hematol (2010) 89:405–409body iron burden. Patients also had high mean prebaseline
LIC, which moderately correlated with both baseline
cardiac T2* and serum ferritin levels (r=−0.52 and 0.53,
respectively). Mean deferasirox dose in all patients was
25.9±2.3 mg/kg/day at baseline in this extended study,
which increased to 32.0±4.4 mg/kg/day at 6 months and
37.7±5.5 mg/kg/day at 18 months. When the data were
analyzed by baseline cardiac T2* subgroups (<10 ms [n=6],
10–20 ms [n=7], and >20 ms [n=6]), all subgroups
demonstrated high baseline serum ferritin levels and prebase-
line LIC (Fig. 1). Mean prebaseline LIC had a stronger
positive correlation with baseline cardiac T2* in the >20-ms
cardiac T2* subgroup (r=0.72) than the 10–20 ms (r=0.18)
and <10-ms subgroups (r=−0.64). Conversely, mean pre-
baseline LIC correlated more strongly with serum ferritin
levels in the <10-ms cardiac T2* subgroup (r=0.60) than the
10–20-ms (r=0.20) and >20-ms subgroups (r=0.18).
Myocardial iron: cardiac T2*
After 6 months of deferasirox therapy, a significant improve-
ment in mean cardiac T2* from 17.2 to 20.8 ms (+20.9%; P=
0.007) was seen. The observed improvement continued
through to 18 months with a mean cardiac T2* of 21.5 ms
(+25.0%; P=0.02; Fig. 1a). There were significant improve-
ments in T2* (P<0.05) at 18 months in both the <10-ms
subgroup (cardiac T2* improved from a mean of 6.3 to
7.8 ms [+23.8%]) and the 10–20-ms subgroup (cardiac T2*
improved from a mean of 14.9 to 21.4 ms [+43.6%];
Fig. 1a). There was also a significant improvement in T2*
after 6 months in the >20-ms subgroup (cardiac T2*
improved from a mean of 30.8 to 37.2 ms [+20.8%]); after
18 months, cardiac T2* was 35.2 ms (Fig. 1a), representing
an average improvement of 14.3% compared with baseline.
Total body iron: LIC and serum ferritin
Deferasirox treatment significantly reduced LIC from 24.2±
9.0 mg Fe/g dw prebaseline to 17.6±12.9 mg Fe/g dw at
18 months (−27.1%; P=0.01) in the overall study population
(Fig. 1b). The reductions in LIC (−56.6%) were also
significant after 18 months in the >20-ms cardiac T2*
subgroup; LIC was reduced by 8.1 and 10.2 mg Fe/g dw at
6( P≤0.01) and 18 months (P≤0.05), respectively, from a
prebaseline value of 18.0 mg Fe/g dw (Fig. 1b). Although not
statistically significant, LIC was reduced in both the <10-ms
and 10–20-ms cardiac T2* subgroups after 18 months of
therapy (−32.3% and –3.4%, respectively); however, in the
10–20-ms subgroup after 6 months, there was a marginal rise
(Fig. 1b); whereas, the trend in the other two subgroups and
overall was downwards. Serum ferritin was also significantly
reduced from baseline median 5,497 to 4,235 ng/mL
(–23.0%; P=0.001) after 18 months of deferasirox treatment
in the overall study population (Fig. 1c). In the >20-ms
cardiac T2* subgroup, serum ferritin was reduced (–62.1%)
after 18 months; serum ferritin fell by 1,703 and 2,940 ng/mL
at 6 and 18 months (P≤0.01 for both), respectively, from
a baseline value of 4,733 ng/mL (Fig. 1c). After 18 months
of therapy, serum ferritin was reduced by 7.0% and 15.3%
in the <10-ms and 10–20-ms cardiac T2* subgroups,
respectively (not statistically significant).
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Fig. 1 Efficacy of deferasirox after 6 and 18 months of therapy with
respect to changes in a mean cardiac T2*, b mean LIC, and c median
serum ferritin by cardiac T2* subgroup. Triangle, <10 ms (n=6);
square, 10–20 ms (n=7); diamond, >20 ms (n=6); circle, all patients
(n=19); *P≤0.05; **P≤0.01; ***P≤0.001; BL, baseline;
†These
values were measured 3–6 months prior to baseline T2* MRI
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Deferasirox therapy significantly improved cardiac T2* in
this group of heavily iron-overloaded β-thalassemia patients
at doses that were progressively escalated to >30 mg/kg/day
over a period of 18 months of continued therapy. Inour study
group, we observed that although 65% of patients had
significant myocardial iron overload as defined by T2*<
20 ms, improvements in cardiac T2* were seen in patients
with various degrees of cardiac siderosis, including those
patients with baseline cardiac T2* of <10 ms. This indicates
that deferasirox is effective in removing iron from the heart in
patients with mild, moderate, and severe cardiac siderosis.
Overallserum ferritinandLICwerealsosignificantlyreduced
in all patients. When data were analyzed by baseline T2*
subgroup,the reductioninthese markersoftotalbodyirondid
not reach statistical significance in the <10-ms and 10–20-ms
subgroups. This was possibly due to the small number of
patients in the study and the extremely heavy prebaseline iron
burden in these patients; however, measurements of LIC and
serum ferritin were reduced from baseline. These data suggest
that deferasirox is capable of removing cardiac iron in cardiac
iron-overloaded patients while also decreasing total body iron
burden. Deferasirox was also shown to continue removal of
total body iron in iron-overloaded patients while protecting
them from developing cardiac overload as demonstrated in the
cardiac T2* >20-ms subgroup.
Statistically significant improvements in myocardial T2*
have recently been reported as part of the deferasirox
evaluation of patients iron chelation (EPIC) trial in a larger
group of β-thalassemia patients (n=114) treated with defer-
asirox over a 1-year period [12]. A subgroup of β-thalassemia
patients (n=78) with normal cardiac iron levels were also
shown to maintain normal cardiac iron while reducing total
body iron levels [13]. In our study, there was differential
improvement in the first 6 months versus the last 12 months
of treatment based on the slope of mean LIC and mean serum
ferritin plots. The slope was steeper in the first 6 months,
which may reflect better chelator efficiency when the iron
overload was higher. Interestingly, this is also correlated with
the slope of improvement in the mean cardiac T2* plot
(Fig. 1a) which is indicative of congruous and simultaneous
cardiac and liver iron overload chelation. Our study results,
although obtained on a small sample size, are reflective of
similar results already reported by the much larger EPIC
study [12].
However, longitudinal analyses of cardiac and liver iron
content in response to chelation therapy have indicated that
iron is removed from the heart at a slower rate as compared
with the liver [18], highlighting the importance of long-term
studies to observe changes in iron content in these organs.
Our study also shows a similar trend. When comparing the
slope of change in mean LIC and serum ferritin plots against
the slope of mean cardiac T2*, the slope appears steeper in
the former as compared with the latter for the two
corresponding study periods in the subgroup analysis
(Fig. 1a, b, and c). This would seem to indicate that iron
is being chelated at a faster rate from the liver than the
heart, although an unidirectional trend would confirm that
chelation is being achieved at both sites. The only
aberration was noticed in the 10–20-ms subgroup where,
after an initial improvement, there was a marginally
opposite trend, one explanation for which may be due to
poor compliance in a few patients.
A further point of consideration is that these results were
achieved based on an ongoing dynamic strategy to adjust
the chelator dose to meet the level of iron overload at any
given point in the study period. This was done by looking
at the trends seen with markers of iron overload namely
serial serum ferritin levels and LIC values. Thus, the chelator
dose was progressively increased if parameters of iron
overload showed a rising trend and reduced progressively if
an opposite trend was seen at any time point in the study. This
wasdonewiththedualaimofprovidingoptimalchelationand
minimizing the precipitation of any side effects. In this
context,lookingatthesubgroups,the>20-msgroupremained
within the normal range with the maximal benefit seen in the
first 6 months. The 10–20 ms subgroup showed a steady
improvement, which was better than the <10-ms subgroup,
although both improved. The comparatively poorer improve-
ment in the <10-ms subgroup may be due to the very severe
cardiac siderosis andveryhighironoverloadinthissubgroup.
Recently, few published studies have shown that cardiac T2*
does not correlate with the degree of LIC and serum ferritin
[19–21]. However, this was not so in our study patients.
None of our patients with high LIC had normal myocardial
iron, and all received the same single oral chelator. Currently,
therefore, although deferiprone alone or in combination with
DFO has a proven efficacy to remove myocardial iron, in our
study patients, the improvement in the cardiac T2* was
purely following deferasirox therapy. Overall, these initial
results are encouraging for the use of deferasirox in the
treatment and prevention of cardiac iron overload as well as
in the reduction of total body iron. Additional, longer-term
studies with larger groups of patients will contribute
further to our understanding of the efficacy of defer-
asirox in the removal and prevention of cardiac iron
overload.
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